HEALTHCARE RESOURCE UTILIZATION FOLLOWING HUMAN METAPNEUMOVIRUS (HMPV) OR RESPIRATORY SYNCYTIAL VIRUS (RSV) DIAGNOSIS IN ADULTS: A RETROSPECTIVE, SELF-CONTROLLED, CLAIMS-BASED STUDY IN THE UNITED STATES
Author(s)
Renee L. Gennarelli, MS1, Lisa Glasser, MD2, Daniel Molnar, MS3, Chengbin Wang, MD4, Corey Fang, PharmD2, Casey Dobie, PharmD1, Temitope Bello, MS1, Angela Branche, MD5;
1Cencora, Inc., Global Consulting Services, Conshohocken, PA, USA, 2AstraZeneca BioPharmaceuticals Medical, Vaccines & Immune Therapies, Wilmington, DE, USA, 3AstraZeneca Farmacéutica Spain S.A., Vaccines & Immune Therapies, Barcelona, Spain, 4AstraZeneca BioPharmaceuticals Medical, Vaccines & Immune Therapies, Gaithersburg, MD, USA, 5University of Rochester, Division of Infectious Diseases, Department of Medicine, Rochester, NY, USA
1Cencora, Inc., Global Consulting Services, Conshohocken, PA, USA, 2AstraZeneca BioPharmaceuticals Medical, Vaccines & Immune Therapies, Wilmington, DE, USA, 3AstraZeneca Farmacéutica Spain S.A., Vaccines & Immune Therapies, Barcelona, Spain, 4AstraZeneca BioPharmaceuticals Medical, Vaccines & Immune Therapies, Gaithersburg, MD, USA, 5University of Rochester, Division of Infectious Diseases, Department of Medicine, Rochester, NY, USA
OBJECTIVES: Testing for hMPV is less frequent and its burden is less well understood than RSV. This study sought to address critical gaps in post pandemic data by quantifying healthcare resource utilization (HCRU) following hMPV and RSV infections in adults, focusing on outpatient (OP) encounters.
METHODS: This retrospective, self-controlled cohort study utilized Komodo Health claims data to identify adults with ICD-10 codes for hMPV or RSV between March 2022 and November 2024. Mean all-cause HCRU was estimated during the 12 months before and after infection using multivariable generalized estimating equations. Mean infection-related HCRU was derived by calculating mean monthly differences between baseline and follow-up estimates to understand the temporal distribution of burden following infection.
RESULTS: A total of 13,682 adults with hMPV were included. hMPV patients with ≥1 predefined chronic medical condition (CMC+; n=8613) experienced an average of 4.34 (95% CI: 4.16, 4.53) all cause monthly OP encounters (e.g., office visit, labs, therapy, imaging) during baseline, increasing to 6.35 (6.12, 6.59) in Month 1 post-infection and gradually returning to baseline by Month 7. hMPV patients with no predefined CMCs (CMC−; n=5069) had an average of 1.73 (1.60, 1.86) all-cause monthly OP encounters during baseline, increasing to 3.73 (3.50, 3.98) in Month 1 post-infection; however, they did not fully return to baseline within the 12 months post-infection. The estimated cumulative average of additional hMPV-related OP encounters (over baseline) for CMC+ and CMC− hMPV patients was 5.84 and 5.73, respectively, in the 6 months post-infection. Results were similar in the RSV cohort.
CONCLUSIONS: The 6-month cumulative average of additional infection-related OP encounters (over baseline) was similar in patients with or without CMCs. These findings highlight the healthcare burden associated with hMPV and RSV infections and underscore the need for targeted interventions to reduce the occurrence and severity of both hMPV and RSV infections.
METHODS: This retrospective, self-controlled cohort study utilized Komodo Health claims data to identify adults with ICD-10 codes for hMPV or RSV between March 2022 and November 2024. Mean all-cause HCRU was estimated during the 12 months before and after infection using multivariable generalized estimating equations. Mean infection-related HCRU was derived by calculating mean monthly differences between baseline and follow-up estimates to understand the temporal distribution of burden following infection.
RESULTS: A total of 13,682 adults with hMPV were included. hMPV patients with ≥1 predefined chronic medical condition (CMC+; n=8613) experienced an average of 4.34 (95% CI: 4.16, 4.53) all cause monthly OP encounters (e.g., office visit, labs, therapy, imaging) during baseline, increasing to 6.35 (6.12, 6.59) in Month 1 post-infection and gradually returning to baseline by Month 7. hMPV patients with no predefined CMCs (CMC−; n=5069) had an average of 1.73 (1.60, 1.86) all-cause monthly OP encounters during baseline, increasing to 3.73 (3.50, 3.98) in Month 1 post-infection; however, they did not fully return to baseline within the 12 months post-infection. The estimated cumulative average of additional hMPV-related OP encounters (over baseline) for CMC+ and CMC− hMPV patients was 5.84 and 5.73, respectively, in the 6 months post-infection. Results were similar in the RSV cohort.
CONCLUSIONS: The 6-month cumulative average of additional infection-related OP encounters (over baseline) was similar in patients with or without CMCs. These findings highlight the healthcare burden associated with hMPV and RSV infections and underscore the need for targeted interventions to reduce the occurrence and severity of both hMPV and RSV infections.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE231
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Infectious Disease (non-vaccine), SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)